Home Genome Editing Gene Therapy Kriya Raises $270M Series C toward Fully Integrated Gene Therapy Engine

kriya therapeutics — Kriya Therapeutics, a fully-integrated gene therapy developer with operations in North Carolina's Research Triangle Park (pictured) and Redwood City, CA, said today it has completed a $270 million Series C financing that is intended to support the advancement of its pipeline and continued scaling of its engineering, manufacturing, and computational platforms. [Kriya Therapeutics]

Kriya Raises $270M Series C toward Fully Integrated Gene Therapy Engine

With operations in Redwood City, CA, and Research Triangle Park, NC, Kriya is building distinct gene therapy capabilities and a pipeline of therapeutics across multiple disease areas.

By Jonathan D Grinstein, PhD

May 16, 2022

Kriya Therapeutics, a fully-integrated gene therapy developer with operations in North Carolina's Research Triangle Park (pictured) and Redwood City, CA, said today it has completed a $270 million Series C financing that is intended to support the advancement of its pipeline and continued scaling of its engineering, manufacturing, and computational platforms. [Kriya Therapeutics]

Kriya was founded on the idea that consolidating critical capabilities into one company would enable efficient, systematic delivery of new gene therapy products and technologies across multiple different problems, expanding the field's reach to tackle broader universal diseases. While a top-down approach of starting with a single asset and then figuring out how to manufacture it is typical, Kriya asserts that it is coming at gene therapy from the opposite end, building its manufacturing infrastructure and analytical platform to advance dozens of products . . .